About the Healthcare Industries Cluster
The Berlin-Brandenburg region is one of the leading life sciences and healthcare industries centers in the world. The region’s main strengths are its unique concentration of science, clinics and business and the close network they maintain. Numerous technology parks and networks in different fields, above all biotechnology and medical technology, create an ideal infrastructure for transforming the latest scientific findings into innovative products for the healthcare sector. The systematic innovation policy under the joint innovation strategy of the states Berlin and Brandenburg (innoBB) aims to expand the cluster's development and drive top performance for the regional and global healthcare markets.
The cluster managers welcome you to the HealthCapital cluster website!
Biotechnology and Pharmaceuticals
With cutting-edge research and development from molecules to products, biotechnology in the capital region provides an excellent environment for global players in the pharmaceuticals industry and top scientists.
World leaders in medical technology – many of the over 300 medical technology companies in Berlin-Brandenburg can claim this title. They benefit from the close network between science, business and clinics here.
Innovative Patient Care & Rehabilitation
For medical care and rehabilitation or nursing care – in the capital region, patients of all ages will benefit from capable, highly networked medical care at the highest level.
Health Tourism & Prevention
Berlin-Brandenburg is one of the most attractive healthcare regions with an international flair. It provides lots of space and a wide range of services for prevention, medical tourism and wellness.
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like...
Adrenomed AG receives approval to conduct proof of concept study with Adrecizumab to treat patients with early septic shock
Germany first country to grant full approval for Phase II study ADR-02 (AdrenOSS-2) with Adrecizumab in patients with early septic shock • ADR-02 study to enroll 300 patients in Germany, Belgium, France and the Netherlands for...
Eckert & Ziegler Q2 / 2017: Income Surges Following Sale of Cyclotron Unit. Net Liquidity Exceeds € 40 Million. Group Almost Debt-free.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a Berlin-based company specializing in isotope technology for medical, scientific and industrial applications, nearly doubled its profit per share by 0.91 EUR...
Information will follow soon.
In regenerative medicine, the efficient development of new therapy options, such as cell therapies, requires suitable in-vitro disease model systems beyond the current standard.
Innovative bioanalytics in food and in humans
INTERNATIONAL TECHNOLOGY FORUM ON IN VITRO-DIAGNOSTICS AND BIOANALYSIS & POTSDAM COLLOQUIUM ON BIOANALYSIS